WATCH LIVE
timothy sykes logo
RLMD Jumps As H.C. Wainwright Launches Bullish Coverage Thumbnail
G Google News

RLMD Jumps As H.C. Wainwright Launches Bullish Coverage

TIM SYKES•UPDATED JUN. 26, 2026, 4:08 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Relmada Therapeutics Inc. stocks have been trading up by 3.72 percent following upbeat sentiment on its late-stage drug pipeline prospects.

What Traders Need To Know

  • H.C. Wainwright started coverage with a Buy rating and a $12 price target, signaling renewed Wall Street attention on RLMD.
  • NDV-01, a sustained-release intravesical chemotherapy for non-muscle invasive bladder cancer, is flagged as a next-generation delivery platform.
  • The new Buy call lines up with an already positive analyst view and an average target near $12.67, clustering expectations in the low-teens.
  • This upbeat coverage arrives as RLMD trades around the mid-$6 area, creating a wide gap between price and targets.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Friday, June 26, 2026 Relmada Therapeutics Inc. stock [NASDAQ: RLMD] is trending up by 3.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Relmada Therapeutics (RLMD) is a pre‑revenue, clinical‑stage biotech with a small enterprise value of ~$14.2M and no debt, anchored by exceptionally strong liquidity (current and quick ratios both ~18x) and large working capital of ~$222M. Profitability metrics are deeply negative (ROE ~‑71%, ROA ~‑45%), consistent with heavy R&D spend and no product sales. Q1 2026 operating cash burn of ~$15M and net loss of ~$19M underscore dependency on capital markets despite a sizable equity cushion.

Technically, RLMD has been in a short, low‑liquidity compression phase this week, trading in a tight 6.45–6.89 range, with the latest close at 6.69. Intraday 5‑minute candles show modest mean‑reversion flows rather than directional momentum, with thin volume amplifying small price moves. The dominant near‑term trend is sideways to slightly bearish below 6.90 resistance. A specific actionable level is support near 6.45; a sustained break below that level would trigger a short‑term downside trade toward the low‑6s.

Recent initiation by H.C. Wainwright with a Buy and $12 target, focused on NDV‑01 in non‑muscle invasive bladder cancer, places RLMD at a discount to its own coverage and above-average upside versus Healthcare and Biotechnology & Life Sciences indices. Analyst targets (~$12–12.67) imply substantial appreciation from current levels. Key near‑term levels are support at 6.45 and resistance at 7.50; base case 12‑month target is 10, contingent on NDV‑01 clinical execution and disciplined cash burn.

More Breaking News

Quick Financial Overview

Relmada Therapeutics Inc. is trading in the mid-$6 range, with the weekly data showing action between about $6.45 and $6.89 into 2026/06/26. Price has pulled back from early-week highs but is holding above the recent weekly low, suggesting a consolidation rather than a breakdown. Intraday on the latest session, RLMD opened near $6.40 in early trade, dipped briefly, then climbed into the $6.80–$6.90 zone before closing around $6.69. That intraday ramp and hold near the top of the day’s range is the kind of pattern traders watch for continued momentum.

Financially, RLMD is a classic clinical-stage biotech profile. The company booked a quarterly net loss of about $19.1M, or roughly -$0.22 per share, for the period ending 2026/03/31. Operating cash flow was negative at about -$15.1M, with free cash flow also around -$15.1M, reflecting high research and development and general and administrative spend. The negative returns on assets and equity show that Relmada Therapeutics Inc. is still firmly in the capital-consuming, data-driven phase rather than cash-generation mode.

At the same time, the balance sheet is a key part of the trading story. RLMD reported total assets of roughly $235.4M and stockholders’ equity near $218.7M, with no long-term debt and current liabilities around $12.9M. Liquidity is strong, with a current ratio of about 18.3 and a quick ratio of 18.2, backed by over $233.9M in cash and short-term investments. With book value per share around $2.09 and a price-to-book near 3.61, traders are paying a premium for the pipeline and upcoming catalysts rather than current earnings.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”